• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Determination of the Dynamically Linked Indices of Fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model.在中空纤维感染模型中测定绿脓假单胞菌的磷霉素动态相关指数。
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.02627-17. Print 2018 Jun.
2
The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model.磷霉素与美罗培南联合使用对绿脓假单胞菌 PAO1 在中空纤维感染模型中具有协同作用。
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.01682-18. Print 2018 Dec.
3
Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.美罗培南与磷霉素联合对产金属β-内酰胺酶铜绿假单胞菌协同作用的药效学达成。
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00126-19. Print 2019 Jun.
4
Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model.磷霉素单剂和多剂口服给药对动态体外膀胱感染模型中铜绿假单胞菌尿路感染的疗效。
J Antimicrob Chemother. 2020 Jul 1;75(7):1879-1888. doi: 10.1093/jac/dkaa127.
5
Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.磷霉素与多黏菌素B、妥布霉素或环丙沙星联用的临床相关浓度可增强对铜绿假单胞菌的杀菌作用,但不能抑制磷霉素耐药性的产生。
J Antimicrob Chemother. 2016 Aug;71(8):2218-29. doi: 10.1093/jac/dkw115. Epub 2016 Apr 26.
6
In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.磷霉素对铜绿假单胞菌临床分离株的体外药效学
J Antimicrob Chemother. 2015 Nov;70(11):3042-50. doi: 10.1093/jac/dkv221. Epub 2015 Jul 24.
7
Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy.雾化吸入磷霉素和阿米卡星对中空纤维感染模型中铜绿假单胞菌和肺炎克雷伯菌耐药临床分离株的药效学:联合治疗的实验依据
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.01763-16. Print 2017 Jan.
8
Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model.利用动态体外模型阐明磷霉素对铜绿假单胞菌活性的药代动力学/药效学决定因素。
J Antimicrob Chemother. 2018 Jun 1;73(6):1570-1578. doi: 10.1093/jac/dky045.
9
Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.磷霉素的药效学:对抗菌药物耐药性临床应用的见解
Antimicrob Agents Chemother. 2015 Sep;59(9):5602-10. doi: 10.1128/AAC.00752-15. Epub 2015 Jun 29.
10
Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.用磷霉素验证针对大肠杆菌和铜绿假单胞菌的突变选择窗假说:一项体外和体内比较研究。
J Antibiot (Tokyo). 2017 Feb;70(2):166-173. doi: 10.1038/ja.2016.124. Epub 2016 Oct 19.

引用本文的文献

1
A freely accessible, adaptable hollow-fiber setup to reproduce first-order absorption: illustration with linezolid cerebrospinal fluid pharmacokinetic data.一种可自由访问、可适应的中空纤维装置,用于重现一级吸收:以利奈唑胺脑脊液药代动力学数据为例进行说明。
Microbiol Spectr. 2025 Jun 3;13(6):e0005125. doi: 10.1128/spectrum.00051-25. Epub 2025 May 15.
2
Optimized fosfomycin regimens for treating carbapenem-resistant Acinetobacter baumannii in critically ill patients with varying degrees of renal function.优化的磷霉素方案治疗不同肾功能严重程度的危重症患者耐碳青霉烯鲍曼不动杆菌。
Clin Transl Sci. 2024 Oct;17(10):e70038. doi: 10.1111/cts.70038.
3
Intravenous Fosfomycin for Systemic Multidrug-Resistant Infections.静脉注射磷霉素治疗全身性多重耐药感染
Antibiotics (Basel). 2023 Nov 23;12(12):1653. doi: 10.3390/antibiotics12121653.
4
pharmacokinetics/pharmacodynamics of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against complex.β-内酰胺酶抑制剂达芦那韦与舒巴坦联合对复杂感染的药代动力学/药效学。
Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0031223. doi: 10.1128/aac.00312-23. Epub 2023 Dec 11.
5
The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy.静脉注射磷霉素在临床实践中的应用:意大利一家三级医院的5年回顾性研究
Antibiotics (Basel). 2023 May 27;12(6):971. doi: 10.3390/antibiotics12060971.
6
Predicting Antimicrobial Activity at the Target Site: Pharmacokinetic/Pharmacodynamic Indices versus Time-Kill Approaches.预测靶部位的抗菌活性:药代动力学/药效学指标与时间杀菌法
Antibiotics (Basel). 2021 Dec 4;10(12):1485. doi: 10.3390/antibiotics10121485.
7
Development and Validation of an HPLC-UV Method for Quantitation of Linezolid: Application to Resistance Study Using in vitro PK/PD Model.一种用于定量利奈唑胺的高效液相色谱-紫外检测法的建立与验证:在体外药代动力学/药效学模型用于耐药性研究中的应用
Infect Drug Resist. 2021 Dec 1;14:5089-5098. doi: 10.2147/IDR.S343200. eCollection 2021.
8
Polymyxin B Pharmacodynamics in the Hollow-Fiber Infection Model: What You See May Not Be What You Get.多粘菌素 B 在中空纤维感染模型中的药效学:所见未必所得。
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0185320. doi: 10.1128/AAC.01853-20.
9
Activity of fosfomycin and amikacin against fosfomycin-heteroresistant strains in a infection model.磷霉素和阿米卡星在感染模型中对磷霉素异质性耐药菌株的活性。
Antimicrob Agents Chemother. 2023 May 1;65(5). doi: 10.1128/AAC.02213-20. Epub 2021 Mar 8.
10
Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction.群体药代动力学和蒙特卡罗模拟用于优化磷霉素在治疗无肾功能不全患者骨关节炎感染中的剂量。
Antimicrob Agents Chemother. 2023 May 1;65(5). doi: 10.1128/AAC.02038-20. Epub 2021 Feb 22.

本文引用的文献

1
Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.ZTI-01(注射用磷霉素)在中性粒细胞减少小鼠大腿感染模型中对大肠杆菌、肺炎克雷伯菌和铜绿假单胞菌的药代动力学和药效学
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00476-17. Print 2017 Jun.
2
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2.抑制病原菌耐药性的产生:做好充分准备,第二部分
Antimicrob Agents Chemother. 2015 Dec 28;60(3):1194-201. doi: 10.1128/AAC.02231-15.
3
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.抑制病原菌耐药性的产生:做好准备,第一部分
Antimicrob Agents Chemother. 2015 Dec 28;60(3):1183-93. doi: 10.1128/AAC.02177-15.
4
Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.磷霉素的药效学:对抗菌药物耐药性临床应用的见解
Antimicrob Agents Chemother. 2015 Sep;59(9):5602-10. doi: 10.1128/AAC.00752-15. Epub 2015 Jun 29.
5
Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.使用体外感染模型探索磷霉素疗效的药代动力学-药效学关系
Antimicrob Agents Chemother. 2015 Dec;59(12):7170-7. doi: 10.1128/AAC.04955-14. Epub 2015 Jun 22.
6
Phosphonomycin, a new antibiotic produced by strains of streptomyces.磷霉素,一种由链霉菌菌株产生的新型抗生素。
Science. 1969 Oct 3;166(3901):122-3. doi: 10.1126/science.166.3901.122.

在中空纤维感染模型中测定绿脓假单胞菌的磷霉素动态相关指数。

Determination of the Dynamically Linked Indices of Fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model.

机构信息

Institute for Therapeutic Innovation, University of Florida, Lake Nona, Florida, USA.

Institute for Therapeutic Innovation, University of Florida, Lake Nona, Florida, USA

出版信息

Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.02627-17. Print 2018 Jun.

DOI:10.1128/AAC.02627-17
PMID:29581114
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5971584/
Abstract

Fosfomycin is the only expoxide antimicrobial and is currently under development in the United States as an intravenously administered product. We were interested in identifying the exposure indices most closely linked to its ability to kill bacterial cells and to suppress amplification of less susceptible subpopulations. We employed the hollow fiber infection model for this investigation and studied wild-type strain PAO1. Because of anticipated rapid resistance emergence, we shortened the study duration to 24 h but sampled the system more intensively. Doses of 12 and 18 g/day and schedules of daily administration, administration every 8 h, and administration by continuous infusion for each daily dose were studied. We measured fosfomycin concentrations (by liquid chromatography-tandem mass spectrometry), the total bacterial burden, and the burden of less susceptible isolates. We applied a mathematical model to all the data simultaneously. There was a rapid emergence of resistance with all doses and schedules. Prior to resistance emergence, an initial kill of 2 to 3 log(CFU/ml) was observed. The model demonstrated that the area under the concentration-time curve/MIC ratio was linked to total bacterial kill, while the time that the concentration remained above the MIC (or, equivalently, the minimum concentration/MIC ratio) was linked to resistance suppression. These findings were also seen in other investigations with ( systems) and (murine system). We conclude that for serious infections with high bacterial burdens, fosfomycin may be of value as a new therapeutic and may be optimized by administering the agent as a continuous or prolonged infusion or by use of a short dosing interval. For indications such as ventilator-associated bacterial pneumonia, it may be prudent to administer fosfomycin as part of a combination regimen.

摘要

磷霉素是唯一的环氧化物抗菌药物,目前正在美国开发为静脉内给药产品。我们有兴趣确定与杀死细菌细胞和抑制敏感性较低的亚群扩增能力最密切相关的暴露指数。我们为此研究采用了中空纤维感染模型,并研究了野生型菌株 PAO1。由于预期会迅速产生耐药性,我们将研究时间缩短至 24 小时,但更密集地采样系统。研究了每天 12 克和 18 克的剂量以及每天给药、每 8 小时给药和连续输注每个每日剂量的方案。我们测量了磷霉素浓度(通过液相色谱-串联质谱法)、总细菌负荷和敏感性较低分离物的负荷。我们同时对所有数据应用了数学模型。所有剂量和方案都迅速出现了耐药性。在耐药性出现之前,观察到初始杀灭 2 到 3 对数(CFU/ml)。该模型表明浓度-时间曲线下面积/MIC 比值与总细菌杀灭有关,而浓度保持在 MIC 以上的时间(或等效地,最小浓度/MIC 比值)与耐药性抑制有关。在其他使用 (系统)和 (鼠系统)的研究中也观察到了这些发现。我们的结论是,对于高细菌负荷的严重感染,磷霉素作为一种新的治疗方法可能具有价值,通过连续或延长输注或使用短的给药间隔来优化该药物的给药。对于呼吸机相关细菌性肺炎等适应症,作为联合治疗方案的一部分使用磷霉素可能是谨慎的。